期刊文献+

我院2006—2007年抗糖尿病药物应用情况分析 被引量:3

Application Analysis of Antidiabetic Drugs in Our Hospital during 2006—2007
下载PDF
导出
摘要 目的了解医院抗糖尿病药物的应用情况和趋势。方法采用销售金额和用药频度(DDDs)排序法,对医院2006—2007年抗糖尿病药物的用药金额、DDDs及日均费用(DDDc)进行统计和分析。结果门诊抗糖尿病药物用药金额大于住院;胰岛素及其类似物、α-糖苷酶抑制剂和胰岛素增敏剂居用药金额的前3位;DDDs居前3位的药品依次为诺和灵30R笔芯、二甲双胍片、胰岛素注射液;与2006年相比,2007年抗糖尿病药物DDDs增长30.61%,用药总金额增长22.56%,而所有药品的DDDc较上年均有下降。结论该院抗糖尿病药物用药结构稳定,用药数量和金额逐年增长。抗糖尿病药物DDDc随着药品价格的降低而下降。 Objective To investigate the current situation and developing trend of antidiabetic drugs used in our hospital. Methods The antidiabetic drugs used in our hospital during 2006- 2007 were analyzed statistically in sales amount, DDDs and DDDc. Results The sales amount of antidiabetic drugs in the outpatients was higher than that in the inpatients. The top 3 antidiabetic drugs in respect of sales amount were insulin and insulin similitude, c^- glucosidase inhibitor and insulin sensitizer. The top 3 antidiabetic drugs in respect of DDDs were Novolin 30R, Metformin Tablets and Regular Insulin Injection. Compared with 2006, DDDs for antidiabetic drugs in 2007 increased by 30. 61%, the sales amount for antidiabetic drugs in 2007 increased by 22.56%. But DDDc of the antidiabetic drugs decreased in 2007. Conclusion There was a stable and rational structure of antidiabetic drugs in our hospital during this period. The use amount and consumption sum of antidiabetic drugs kept increasing year by year. DDDc of antidiabetic drugs decreased gradually with declining prices.
作者 南家林
出处 《中国药业》 CAS 2009年第22期57-58,共2页 China Pharmaceuticals
关键词 抗糖尿病药物 销售金额 用药频度 日用药金额 分析 anti - diabetic drugs sales value DDDs DDDc analysis
  • 相关文献

参考文献2

二级参考文献26

  • 1[1]Renstrom E,Barg S,Thevenod F,et al.Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K+ channelindependent action[J].Diabetes,2002,51(suppl 1):s33.
  • 2[2]Renstrom E,Barg s,Thevenod F,et al.Sulfonylurea_mediated stimulation of insulin exocytosis via an ATP-sensitive K+ channel-independent action[J].Diabetes,2002,51 (Suppl 1):S33-S36
  • 3[4]Muller G.Dynamics of plasma membrance microdomains and crosstalk to the insulin signalling cascade[J].FEBS Lett,2002,531:81.
  • 4[5]CroopL C,Pelkonen R,Koskimies S,et al.Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes[J].Diabetes Care,1986,9:129.
  • 5[6]U K Prospective Diabetes Study(UKPDS) Group.Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J].Lancet,1998,352:837.
  • 6[7]Menger C,Ione K,William C,et al.Pharmacokinetics and pharmacodynamics of extended-release Glipizide GITS compared with immediate-release Glipide in patients with Type 2 diabetes Mellitus[J].Journal of Clinical Pharmacology,2002,42:651.
  • 7[8]Glipizide GITS Extended-release Tablets.Product information.Pfizer,Inc,New York,1994.
  • 8[9]Egbaria K,Ramachandnm C,Weiner N.Topical application of liposomally entrapped cyclosporin ivaluated by in vitro diffusion studies with human skin[J].Skin Pharmacol,1991,4(1):21.
  • 9[10]Morley JE,Perry HM.The management of diabetes mellitusin older individuals[J].Drugs,1991,41:548.
  • 10[11]Rydberg T,Roder M,Jonsson A,et al.Hypoglycemic activity of glyburide(glibenclamide) metabolites in humans[J].Diabetes Care,1994,17:1026.

共引文献15

同被引文献12

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部